
    
      Primary Objective:

      ● To examine the impact of SIGNATERA™ on clinical decision-making regarding continuation,
      discontinuation, escalation, or de-escalation of immunotherapy.

      Secondary Objective:

      ● To prospectively evaluate the utility of SIGNATERA™ as a tool to detect early evidence of
      response or progression in patients with advanced solid tumors receiving immune checkpoint
      inhibitors.
    
  